

Lead identification of TROP2 x PD-L1 x CD3 trispecific antibody using multi-body platform technology

ARKGEN BioScions



ONCOLOGY	Lead
Product Type	Antibody
Indication	NSCLC
Target	TROP2 x PD-L1 x CD3
MoA(Mechanism of Action)	<p>Trispecific T-cell engager binds target-cell antigens TROP2 and PD-L1 and the effector-cell antigen CD3 to recruit and activate T cells, while simultaneously blocking the interaction between PD-L1 and PD-1.</p> <p>Each binding arm is engineered with lower affinity than a monoclonal antibody to minimize on-target, off-tumor toxicity.</p> <p>Concurrent engagement of both target antigens enhances avidity, resulting in improved tumor selectivity and antitumor potency.</p>
Competitiveness	<ul style="list-style-type: none"> - Providing new therapeutic option for NSCLC patients - Increased tumor selectivity via dual targeting - Reduced on-target off-tumor toxicity via lower per-arm affinity - Overcomes antigen heterogeneity and escape - Potentially wider therapeutic window
Development Stage	Lead
Route of Administration	Subcutaneous

Any unauthorized distribution or reproduction of this material is strictly prohibited.